Urinary KIM-1 Concentration Interpreted in Detecting AKI
|
By LabMedica International staff writers Posted on 25 Mar 2019 |

Image: The Urisys 2400 urine analyzer (Photo courtesy of Roche Diagnostics).
Kidney injury molecule-1 (KIM-1) has been identified as a biomarker for the assessment of nephropathy in various chronic kidney diseases (CKD). Extensive KIM-1 expression occurs in proximal tubule cells in patients with confirmed acute tubular necrosis.
Urinary KIM-1 concentrations were also significantly correlated with the expression of tissue KIM-1 in systemic lupus erythematosus patients. Such findings increase the potential use of urinary KIM-1 in the diagnosis or prognosis of CKD, but also results in the difficulties in the interpretation of urinary KIM-1 when it is used in the early detection of acute kidney injury (AKI).
Scientists collaborating with those at Queen’s University (Kingston, ON, Canada) obtained 188 urine samples were obtained from adults with normal kidney filtration. Of which 83 of the 188 showed negative urine protein, erythrocytes and leucocytes were used as normal controls. The remaining 105 samples showed at least one abnormal result suggesting possible pre-existing nephropathy.
Routine urine analysis was performed on an Urysis 2400 analyzer of the hospital core laboratory, using a multi-parameter test cassette that measures pH, protein (albumin), glucose, ketones, bilirubin, urobilinogen, nitrite, erythrocyte, leukocyte esterase, and specific gravity. The urinary KIM-1 concentrations were measured in duplicate for each sample using the Quantikine enzyme-linked immunosorbent assay (ELISA) kit. The limit of detection was 0.009μg/L.
The investigators reported that the results showed significantly increased urinary KIM-1 concentration in protein positive (protein +, erythrocyte +/-, leucocyte+/-) samples compared to controls that were negative for protein, erythrocytes, and leucocytes. Urinary KIM-1 concentrations were significantly higher when proteinuria was at trace concentration (0.25g/L) and correlated with the severity of proteinuria. The creatinine normalized urinary KIM-1 was significantly higher when urine protein was 0.75g/L to 5g/L. The reference interval for urinary KIM-1 was 0 to 4.19 μg/L, and for creatinine normalized urinary KIM-1 0 to 0.58 μg/mmol.
The authors concluded that baseline urinary KIM-1 concentrations were increased when there was detectable urine protein and correlated with its severity. The urinary KIM-1 concentrations should be interpreted with consideration of urine protein levels in individual patients. The study was published on March 7, 2019, in the journal Practical Laboratory Medicine.
Related Links:
Queen’s University
Urinary KIM-1 concentrations were also significantly correlated with the expression of tissue KIM-1 in systemic lupus erythematosus patients. Such findings increase the potential use of urinary KIM-1 in the diagnosis or prognosis of CKD, but also results in the difficulties in the interpretation of urinary KIM-1 when it is used in the early detection of acute kidney injury (AKI).
Scientists collaborating with those at Queen’s University (Kingston, ON, Canada) obtained 188 urine samples were obtained from adults with normal kidney filtration. Of which 83 of the 188 showed negative urine protein, erythrocytes and leucocytes were used as normal controls. The remaining 105 samples showed at least one abnormal result suggesting possible pre-existing nephropathy.
Routine urine analysis was performed on an Urysis 2400 analyzer of the hospital core laboratory, using a multi-parameter test cassette that measures pH, protein (albumin), glucose, ketones, bilirubin, urobilinogen, nitrite, erythrocyte, leukocyte esterase, and specific gravity. The urinary KIM-1 concentrations were measured in duplicate for each sample using the Quantikine enzyme-linked immunosorbent assay (ELISA) kit. The limit of detection was 0.009μg/L.
The investigators reported that the results showed significantly increased urinary KIM-1 concentration in protein positive (protein +, erythrocyte +/-, leucocyte+/-) samples compared to controls that were negative for protein, erythrocytes, and leucocytes. Urinary KIM-1 concentrations were significantly higher when proteinuria was at trace concentration (0.25g/L) and correlated with the severity of proteinuria. The creatinine normalized urinary KIM-1 was significantly higher when urine protein was 0.75g/L to 5g/L. The reference interval for urinary KIM-1 was 0 to 4.19 μg/L, and for creatinine normalized urinary KIM-1 0 to 0.58 μg/mmol.
The authors concluded that baseline urinary KIM-1 concentrations were increased when there was detectable urine protein and correlated with its severity. The urinary KIM-1 concentrations should be interpreted with consideration of urine protein levels in individual patients. The study was published on March 7, 2019, in the journal Practical Laboratory Medicine.
Related Links:
Queen’s University
Latest Immunology News
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
Channels
Molecular Diagnostics
view channel
New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids
Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more
AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy
Liquid biopsies offer a noninvasive way to study cancer by analyzing circulating tumor DNA in body fluids. However, in pediatric brain tumors, the small amount of ctDNA in cerebrospinal fluid has limited... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Rapid Test Promises Faster Answers for Drug-Resistant Infections
Drug-resistant pathogens continue to pose a growing threat in healthcare facilities, where delayed detection can impede outbreak control and increase mortality. Candida auris is notoriously difficult to... Read more
CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
Antibiotic resistance has accelerated into a global health crisis, with projections estimating more than 10 million deaths per year by 2050 as drug-resistant “superbugs” continue to spread.... Read more
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read morePathology
view channel
Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more
New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more
AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







